ESC 365 - Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

ESC Premium Access

Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

Session: Hot Line: Late-Breaking Clinical Trials 4

Topic: Diabetes, dysglycaemia and metabolic syndrome

Speaker: Professor E. Prescott (Copenhagen, DK)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Eva Prescott

Bispebjerg University Hospital, Copenhagen (Denmark)

26 presentations

10 followers

12 more presentations in this session

Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial

Speaker: Professor M. Landray (Oxford, GB)

Discussant review: Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial

Speaker: Professor J. Chapman (Paris, FR)

Panel discussion.

Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study

Speaker: Professor H. Itoh (Tokyo, JP)

Panel discussion.

Access the full session

Hot Line: Late-Breaking Clinical Trials 4

Speakers: Professor E. Prescott, Professor M. Landray, Professor J. Chapman, Professor H. Itoh

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources